Inspire Investing LLC Lowers Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Inspire Investing LLC cut its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 3.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,044 shares of the company’s stock after selling 362 shares during the period. Inspire Investing LLC’s holdings in Omnicell were worth $403,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. GAMMA Investing LLC lifted its holdings in Omnicell by 78.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after buying an additional 553 shares in the last quarter. 1620 Investment Advisors Inc. increased its position in shares of Omnicell by 230.1% during the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock worth $96,000 after acquiring an additional 1,542 shares during the period. Summit Global Investments acquired a new stake in shares of Omnicell in the third quarter valued at $221,000. QRG Capital Management Inc. purchased a new position in Omnicell in the third quarter valued at $231,000. Finally, Everence Capital Management Inc. acquired a new position in Omnicell during the 3rd quarter worth $249,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Wall Street Analysts Forecast Growth

OMCL has been the topic of a number of analyst reports. Wells Fargo & Company reduced their price target on Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. JPMorgan Chase & Co. lifted their price target on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research note on Thursday, November 21st. Benchmark reissued a “buy” rating and issued a $48.00 price objective on shares of Omnicell in a research report on Wednesday, October 9th. Barclays lifted their price objective on shares of Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Finally, Craig Hallum boosted their target price on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $50.00.

Insider Transactions at Omnicell

In related news, Director Mark W. Parrish sold 12,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the transaction, the director now owns 58,427 shares in the company, valued at $2,763,597.10. This trade represents a 17.04 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 2.64% of the company’s stock.

Omnicell Price Performance

Shares of OMCL opened at $43.63 on Friday. Omnicell, Inc. has a 1-year low of $25.12 and a 1-year high of $55.74. The stock has a market cap of $2.02 billion, a PE ratio of -111.87, a price-to-earnings-growth ratio of 29.73 and a beta of 0.78. The firm has a fifty day moving average price of $44.60 and a 200 day moving average price of $42.14.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.